3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
9
Gynecologic
2
Gastrointestinal
2
CNS
2
Breast
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
147
Leukemia, Lymphocytic, Chronic, B-Cell
140
Lymphoma
116
Lymphoma, Non-Hodgkin
112
Leukemia, Myeloid, Acute
95
Leukemia
92
Myelodysplastic Syndromes
90
Hodgkin Disease
68
Lymphoma, B-Cell
61
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
53
Multiple Myeloma
52
Lymphoma, Mantle-Cell
52
Lymphoma, Large B-Cell, Diffuse
50
Lymphoma, Follicular
50
Recurrence
43
Burkitt Lymphoma
41
Hematologic Neoplasms
36
Myeloproliferative Disorders
31
Lymphoma, B-Cell, Marginal Zone
30
Neoplasms, Plasma Cell
20
Primary Myelofibrosis
19
Leukemia, Biphenotypic, Acute
18
Anemia, Refractory, with Excess of Blasts
18
Lymphoma, T-Cell
17
Leukemia, Myelomonocytic, Chronic
15
Graft vs Host Disease
15
Anemia, Aplastic
15
Leukemia, Prolymphocytic
14
Neoplasms
12
Leukemia, B-Cell
12
Interventions
Vorinostat
3
Azacitidine
3
venetoclax
2
trametinib
2
ruxolitinib
2
pertuzumab
2
palbociclib
2
olaparib
2
durvalumab
2
dabrafenib
2
copanlisib
2
aflibercept
2
abiraterone
2
Sunitinib
2
Specimen Handling
2
Sirolimus
2
Nivolumab
2
Immunoglobulin G
2
HhAntag691
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Cyclophosphamide
2
Biopsy
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
fludarabine
×
Lymphoid
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled